Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Zaid Al Kadhimi"'
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTBackground One major limitation for broader applicability of allogeneic hematopoietic cell transplantation (allo-HCT) in the past was the lack of HLA-matched histocompatible donors. Preclinical mouse studies using T-cell depleted haploidentic
Externí odkaz:
https://doaj.org/article/0d5342cfd0f34d9eab336b1de19c2b48
Autor:
Michael Simon, Qin Liu, Lawrence Flaherty, Lawrence G. Lum, Archana Thakur, Abhinav Deol, Kristie Fields, Dana Schalk, Zaid Al-Kadhimi, Vidya Kondadasula, Elyse Tomashewski, Patricia Steele, Melissa Giroux
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Metastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors
Externí odkaz:
https://doaj.org/article/57a46f642d4b4f41b29378a6a4fcd193
Publikováno v:
Cancer and Metastasis Reviews. 42:113-142
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2ea74b6753ceb1a55f1b5497cb471ae
https://doi.org/10.1007/s10555-023-10079-1
https://doi.org/10.1007/s10555-023-10079-1
Autor:
Ritesh Rathore, Qin Liu, William Colaiace, Abby Maizel, Nicola Kouttab, Don S. Dizon, Robert D. Legare, Francis J. Cummings, Gerald A. Colvin, Zaid Al-Kadhimi, Archana Thakur, Lawrence G. Lum
Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions of anti-CD3 × anti-HER2 bispecific antibody (HER2Bi) armed anti-CD3–activated T cells (ATC) in combination with low-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8ca9ce28f709af3abf49d8a78331c0
https://doi.org/10.1158/1078-0432.c.6523541.v1
https://doi.org/10.1158/1078-0432.c.6523541.v1
Autor:
Ritesh Rathore, Qin Liu, William Colaiace, Abby Maizel, Nicola Kouttab, Don S. Dizon, Robert D. Legare, Francis J. Cummings, Gerald A. Colvin, Zaid Al-Kadhimi, Archana Thakur, Lawrence G. Lum
Methods and Materials, Supplementary Tables S1-S6. Table S1. Patient characteristics: Prior chemotherapy, ER/PR/HER2 status, aATC dose, disease status, survival and time to progression data. Table S2. Dose Escalation Table S3. Characteristics and Act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00aef2eb7e8f4d5c9ba8132ee2f5fcea
https://doi.org/10.1158/1078-0432.22457237
https://doi.org/10.1158/1078-0432.22457237
Autor:
Laurence J.N. Cooper, Andrew Raubitschek, David Colcher, Michael C. Jensen, Stephen D. Gillies, Stephen J. Forman, Zaid Al-Kadhimi, David D. Smith, George McNamara, Simon Olivares, Timothy Pfeiffer, Lisa Marie Serrano, Harjeet Singh
Supplementary Video 2 from Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fc4db6ac313743aff937b78034399e3
https://doi.org/10.1158/0008-5472.22366020.v1
https://doi.org/10.1158/0008-5472.22366020.v1
Autor:
Laurence J.N. Cooper, Andrew Raubitschek, David Colcher, Michael C. Jensen, Stephen D. Gillies, Stephen J. Forman, Zaid Al-Kadhimi, David D. Smith, George McNamara, Simon Olivares, Timothy Pfeiffer, Lisa Marie Serrano, Harjeet Singh
Supplementary Video 1 from Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b9ac6d850670d4df1a5930b88ccee86
https://doi.org/10.1158/0008-5472.22366023
https://doi.org/10.1158/0008-5472.22366023
Autor:
Laurence J.N. Cooper, Andrew Raubitschek, David Colcher, Michael C. Jensen, Stephen D. Gillies, Stephen J. Forman, Zaid Al-Kadhimi, David D. Smith, George McNamara, Simon Olivares, Timothy Pfeiffer, Lisa Marie Serrano, Harjeet Singh
Currently, the lineage-specific cell-surface molecules CD19 and CD20 present on many B-cell malignancies are targets for both antibody- and cell-based therapies. Coupling these two treatment modalities is predicted to improve the antitumor effect, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78aa1093a4b5a0e4ecb299341a9257b0
https://doi.org/10.1158/0008-5472.c.6494955.v1
https://doi.org/10.1158/0008-5472.c.6494955.v1
Autor:
Mohammad S Hossain, Ghada M Kunter, Vicky F El-Najjar, David L Jaye, Zaid Al-Kadhimi, Owonikoko K Taofeek, Jian-Ming Li, Edmund K Waller
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184254 (2017)
The expression of checkpoint blockade molecules PD-1, PD-L1, CTLA-4, and foxp3+CD25+CD4+ T cells (Tregs) regulate donor T cell activation and graft-vs-host disease (GvHD) in allogeneic hematopoietic stem cell transplant (allo-HSCT). Detailed kinetics
Externí odkaz:
https://doaj.org/article/7a146293da1742c3b8c5cbe49181eff0
Autor:
Zaid Al-Kadhimi, Michael Callahan, Todd Fehniger, Kathryn E. Cole, Julie Vose, Steven Hinrichs
Publikováno v:
International immunopharmacology. 113
Innate immune cells [Natural killer (NK) and gamma-delta (γδ) T-cells] have the advantage of mediating graft versus leukemia (GVL) without graft versus host disease (GVHD). Therefore, the infusion of activated innate immune cells post allogenic hem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc7589e2f52d4ccadf2b248e1a329f42
https://pubmed.ncbi.nlm.nih.gov/36461582
https://pubmed.ncbi.nlm.nih.gov/36461582